Adamax

Unverified protocol notes

Protocol logic check

Independent evidence

Regulatory status: no approved label identified

Storage

No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.

Contraindications (limited evidence)

• Concurrent Semax use: Adamax is a pharmacokinetically superior derivative of Semax acting on identical TrkB/MC4R/BDNF targets; co-administration produces supraphysiological receptor agonism without incremental benefit while amplifying all stimulant-adjacent adverse effects and accelerating TrkB downregulation; these compounds are absolutely mutually exclusive. Limited / unverified
• Severe anxiety disorders or active panic disorder: Adamax's enhanced CNS penetration amplifies the MC4R-driven dopaminergic activation and arousal effects of the Semax pharmacophore significantly beyond what parent Semax produces; subjects with anxiety disorders may experience pronounced worsening. Limited / unverified
• Active manic episode or bipolar I disorder (manic phase): dopaminergic and noradrenergic amplification from high-CNS-penetrance MC4R agonism can trigger or accelerate manic states in susceptible individuals. Limited / unverified
• Active psychotic disorders: contraindicated for the same reasons as Semax, with greater urgency given the amplified CNS potency. Limited / unverified
• Late-day administration (after noon): the half-life of 1-2 hours means direct receptor activity clears reasonably quickly, but the BDNF transcription and MC4R-driven arousal effects persist several hours; evening administration reliably causes insomnia. Limited / unverified
• Known hypersensitivity to Semax, Adamax, adamantane-modified peptides, or formulation excipients. Limited / unverified
• Concurrent MAOI use: dopaminergic and serotonergic potentiation via MC4R creates serotonin/dopamine excess risk in the presence of monoamine oxidase inhibition. Limited / unverified
• Pregnancy: no safety data; BDNF signaling plays critical roles in fetal neural development; exogenous supraphysiological BDNF stimulation in utero is not established as safe. Limited / unverified
• Breastfeeding: no safety data. Limited / unverified

Side effects (limited evidence)

• Overstimulation: the most expected and dose-dependent adverse effect; characterized by racing thoughts, mental hyperactivity, inability to relax, mild euphoria at higher doses; a direct consequence of amplified MC4R-driven dopaminergic and noradrenergic tone from high CNS-penetrant delivery; managed with dose reduction or Selank co-administration. Limited / unverified
• Insomnia: MC4R arousal activation persists several hours beyond the short plasma half-life; any administration after noon or at doses above individual tolerance reliably produces sleep onset difficulty; morning-only strict dosing is the primary management. Limited / unverified
• Increased resting heart rate: mild tachycardia from adrenergic-adjacent MC4R activation; generally 5-10 BPM above baseline; typically well-tolerated but warrants monitoring. Limited / unverified
• Anxiety and irritability: common at doses above individual tolerance; mechanistically identical to Semax anxiety but with greater intensity due to enhanced CNS delivery. Limited / unverified
• Headache: reported in the initiation phase; possibly related to rapid changes in BDNF-driven cerebrovascular tone; typically self-limiting within the first week. Limited / unverified
• Hair shedding (rare): BDNF elevation from Adamax, amplified relative to Semax, can accelerate hair follicle cycling and produce transient telogen effluvium; same mechanism as documented with Semax but potentially more pronounced. Limited / unverified
• TrkB receptor downregulation: the primary long-term risk of sustained high-dose administration without adequate washout; results in diminished response to subsequent Adamax or Semax cycles; the 4-week washout protocol is the mitigation strategy. Limited / unverified
• Nasal irritation: with intranasal administration specifically; not applicable to subcutaneous route. Limited / unverified
• Mild blood pressure elevation: from adrenergic-adjacent MC4R/dopaminergic activation; rarely clinically significant at standard doses but warrants monitoring in subjects with cardiovascular risk factors. Limited / unverified

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

Sources

• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding